Avapritinib
VOYAGER
Blueprint Medicines · Phase 3 · Completed · Enrollment 476
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Avapritinib 300 mg | 3L or later GIST (n = 240) | 300 mg | ITT | regorafenib 160 mg | median progression-free survival: 4.2 months, primary analysisprogression-free survival hazard ratio vs regorafenib: 1.25 HR, primary analysis; P = .055objective response rate: 17.1%, primary analysis |
| Regorafenib 160 mg | 3L or later GIST (n = 236) | 160 mg | ITT | n/r | median progression-free survival: 5.6 months, primary analysisobjective response rate: 7.2%, primary analysis |